Q-omics provides the consensus-scored NHS profile across patient tissues and cancer cell-line models. NHS expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, NHS is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, NHS RNA expression shows 19,963 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, HNSC, and UVM as cancer lineages where NHS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NHS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NHS survival associations across molecular data types. NHS RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NHS RNA expression–survival associations across cancer types. High NHS expression shows unfavorable associations in UVM and STAD, but favorable associations in UCEC, BLCA, SKCM and SCLC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for NHS RNA expression.
This table summarizes NHS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NHS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NHS shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, LUAD, LUSC and COAD. The HNSC box plot shows higher NHS RNA expression in tumor versus normal tissue (log2 FC = +0.925, t-test p < 0.001).
This table shows molecular features associated with NHS in patient tissues and cancer cell lines. In patient samples, NHS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NHS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
